Abstract Objective To assess the outcome of patients with cancer-related sepsis requiring continuous renal replacement therapy (CRRT) in a single-center pediatric intensive care unit (PICU). Method Children with sepsis who necessitate CRRT from January 2017 to December 2021 were enrolled. The patients with leukemia/lymphoma or solid tumors were defined as underlying cancer. Multivariate logistic regression analysis was performed to identify the death risk factors in patients with cancer-related sepsis. Results A total of 146 patients were qualified for inclusion. Forty-six (31.5%) patients with cancer-related sepsis and 100 (68.5%) non-cancer-related sepsis. The overall PICU mortality was 28.1% (41/146), and mortality was significantly higher in cancer-related sepsis patients compared with non-cancer patients (41.3% vs. 22.0%, p = 0.016). Need mechanical ventilation, p-SOFA, acute liver failure, higher fluid overload at CRRT initiation, hypoalbuminemia, and high inotropic support were associated with PICU mortality in cancer-related sepsis patients. Moreover, levels of IL-6, total bilirubin, creatinine, blood urea nitrogen, and international normalized ratio were significantly higher in non-survivors than survivors. In multivariate logistic regression analysis, pediatric sequential organ failure assessment (p-SOFA) score (OR:1.805 [95%CI: 1.047-3.113]) and serum albumin level (OR: 0.758 [95%CI: 0.581 -0.988]) were death risk factors in cancer-related sepsis receiving CRRT, and the AUC of combined index of p-SOFA and albumin was 0.852 (95% CI: 0.730-0.974). Conclusion The overall PICU mortality is high in cancer-related sepsis necessitating CRRT. Higher p-SOFA and lower albumin were independent risk factors for PICU mortality. cancerrelated cancer related (CRRT singlecenter single center PICU. . (PICU) 201 202 enrolled leukemialymphoma leukemia lymphoma 14 inclusion Fortysix Forty six 31.5% 315 31 5 (31.5% 10 68.5% 685 68 (68.5% noncancerrelated non 281 28 1 28.1 41/146, 41146 41/146 , 41 (41/146) noncancer 41.3% 413 3 (41.3 vs 220 22 0 22.0% 0.016. 0016 0.016 016 0.016) ventilation pSOFA, pSOFA SOFA, SOFA initiation hypoalbuminemia Moreover IL6, IL6 IL 6, 6 IL-6 bilirubin creatinine nitrogen nonsurvivors survivors (p-SOFA OR1.805 OR1805 OR 1.805 805 (OR:1.80 95%CI 95CI CI 95 [95%CI 1.0473.113 10473113 1.047 3.113 047 113 1.047-3.113] (OR 0758 758 0.75 0581 581 0.58 0.988 0988 988 -0.988] 0852 852 0.85 95% (95 0.7300.974. 07300974 0.730 0.974 730 974 0.730-0.974) (PICU 20 31.5 (31.5 68.5 (68.5 2 28. 4114 41/14 4 (41/146 41.3 (41. 22.0 001 0.01 01 IL- OR1 OR1.80 OR180 1805 1.80 80 (OR:1.8 9 0473 1.0473.11 1047311 1047 1.04 3113 3.11 04 11 1.047-3.113 075 75 0.7 058 58 0.5 0.98 098 98 -0.988 085 85 0.8 (9 7300 0.7300.974 0730097 0730 0.73 0974 0.97 73 97 0.730-0.974 31. (31. 68. (68. 411 41/1 (41/14 41. (41 22. 00 0.0 OR1.8 OR18 180 1.8 8 (OR:1. 1.0473.1 104731 104 1.0 311 3.1 1.047-3.11 07 7 0. 05 0.9 09 -0.98 08 ( 0.7300.97 073009 073 097 0.730-0.97 (31 (68 41/ (41/1 (4 OR1. 18 1. (OR:1 1.0473. 10473 3. 1.047-3.1 -0.9 0.7300.9 07300 0.730-0.9 (3 (6 (41/ 1.0473 1.047-3. -0. 0.7300. 0.730-0. 1.047-3 -0 0.7300 0.730-0 1.047- - 0.730-

Although bivalirudin has been recently made available for purchase in China, large-scale analyses on the safety profile of bivalirudin among Chinese patients is lacking. Thus, this study aimed to compare the safety profile of bivalirudin and heparin as anticoagulants in Chinese ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). A total of 1063 STEMI patients undergoing PCI and receiving bivalirudin (n=424, bivalirudin group) or heparin (n=639, heparin group) as anticoagulants were retrospectively enrolled. The net adverse clinical events (NACEs) within 30 days after PCI were recorded, including major adverse cardiac and cerebral events (MACCEs) and bleeding events (bleeding academic research consortium (BARC) grades 2-5 (BARC 2-5)). The incidences of NACEs (10.1 vs 15.6%) (P=0.010), BARC 2-5 bleeding events (5.2 vs 10.3%) (P=0.003), and BARC grades 3-5 (BARC 3-5) bleeding events (2.1 vs 5.5%) (P=0.007) were lower in the bivalirudin group compared to the heparin group, whereas general MACCEs incidence (8.9 vs 6.4%) (P=0.131) and each category of MACCEs (all P>0.05) did not differ between two groups. Furthermore, the multivariate logistic analyses showed that bivalirudin (vs heparin) was independently correlated with lower risk of NACEs (OR=0.508, P=0.002), BARC 2-5 bleeding events (OR=0.403, P=0.001), and BARC 3-5 bleeding events (OR=0.452, P=0.042); other independent risk factors for NACEs, MACCEs, or BARC bleeding events included history of diabetes mellitus, emergency operation, multiple lesional vessels, stent length >33.0 mm, and higher CRUSADE score (all P<0.05). Thus, bivalirudin presented a better safety profile than heparin among Chinese STEMI patients undergoing PCI. China largescale large scale lacking Thus STsegment ST segment (STEMI . (PCI) 106 n=424, n424 n 424 (n=424 n=639, n639 639 (n=639 enrolled (NACEs 3 recorded (MACCEs 25 2 5 2- 25. 2-5)) 10.1 101 10 1 (10. 15.6% 156 15 6 P=0.010, P0010 P P=0.010 , 0 010 (P=0.010) 5.2 52 (5. 10.3% 103 P=0.003, P0003 P=0.003 003 (P=0.003) 35 3- 2.1 21 (2. 5.5% 55 P=0.007 P0007 007 (P=0.007 8.9 89 8 9 (8. 6.4% 64 4 P=0.131 P0131 131 (P=0.131 all P>0.05 P005 05 groups Furthermore OR=0.508, OR0508 OR 508 (OR=0.508 P=0.002, P0002 P=0.002 002 P=0.002) OR=0.403, OR0403 403 (OR=0.403 P=0.001, P0001 P=0.001 001 P=0.001) OR=0.452, OR0452 452 (OR=0.452 P=0.042 P0042 042 P=0.042) mellitus operation vessels 330 33 >33. mm P<0.05. P<0.05 P<0.05) (PCI n=424 n42 42 (n=42 n=639 n63 63 (n=63 2-5) 10. (10 15.6 P001 P=0.01 01 (P=0.010 5. (5 10.3 P000 P=0.00 00 (P=0.003 2. (2 5.5 (P=0.00 8. (8 6.4 P=0.13 P013 13 (P=0.13 P>0.0 P00 OR=0.508 OR050 50 (OR=0.50 OR=0.403 OR040 40 (OR=0.40 OR=0.452 OR045 45 (OR=0.45 P=0.04 P004 04 >33 P<0.0 n=42 n4 (n=4 n=63 n6 (n=6 (1 15. P=0.0 (P=0.01 ( (P=0.0 6. P=0.1 P01 (P=0.1 P>0. P0 OR=0.50 OR05 (OR=0.5 OR=0.40 OR04 (OR=0.4 OR=0.45 >3 P<0. n=4 (n= n=6 P=0. (P=0. P>0 OR=0.5 OR0 (OR=0. OR=0.4 > P<0 n= (n P=0 (P=0 P> OR=0. (OR=0 P< P= (P= OR=0 (OR= (P OR= (OR

Abstract Oysters are the important marine biological resources available to human beings. The oyster shells contain important organic matters, such as amino acids, proteins and peptides. In the present study, the oyster shell peptides (OSP) were prepared, and the in vitro antioxidant activities of OSP were investigated. OSP were obtained by water refluxing extraction, followed by anion-exchange chromatography and reverse-phase C8 column chromatography. Using vitamin C as control, the capacity of OSP in scavenging 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), superoxide anion, hydroxyl and 1,1-diphenyl-2-picrylhydrazine (DPPH) radicals was determined. In addition, using disodium ethylenediamine tetraacetate as control, the capacity of OSP in chelating Fe2+ was determined. Results showed that, OSP had the capacity of scavenging ABTS, superoxide anion, hydroxyl and DPPH radicals and chelating Fe2+. In conclusion, OSP have the antioxidant activities, and can be further developed into functional health food or medicine with related activities.

ABSTRACT About 31 percent of deaths worldwide result from atherosclerotic cardiovascular disease. Hyperlipidemia remains the major risk factor for this disease and therefore, it is necessary to identify antihyperlipidemic compounds for drug development. The crude ethanolic extract of Cryptolepis sanguinolenta (Lindl.) Schltr., Apocynaceae, has demonstrated antihyperlipidemic properties. However, the chemical constituents responsible for this action are unknown. Hence, to identify chemical constituent(s) of C. sanguinolenta with anti-hyperlipidemic effect, five indoloquinoline alkaloids were isolated and evaluated in 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate labeled low density lipoprotein uptake assay using HepG2 cells. The minor alkaloid, isocryptolepine, showed strong activity in promoting low lipid lipoprotein uptake by 1.85-fold. Isocryptolepine may, therefore, serve as a lead compound for future studies in the development of novel antihyperlipidemic drugs.

ABSTRACT Objective Pendred syndrome (PS) is an autosomal recessive disorder characterised by sensorineural hearing loss and thyroid dyshormonogenesis. It is caused by biallelic mutations in the SLC26A4 gene encoding for pendrin. Hypothyroidism in PS can be present from birth and therefore diagnosed by neonatal screening. The aim of this study was to examine the SLC26A4 mutation spectrum and prevalence among congenital hypothyroidism (CH) patients in the Guangxi Zhuang Autonomous Region of China and to establish how frequently PS causes hearing impairment in our patients with CH. Subjects and methods Blood samples were collected from 192 CH patients in Guangxi Zhuang Autonomous Region, China, and genomic DNA was extracted from peripheral blood leukocytes. All exons of the SLC26A4 gene together with their exon-intron boundaries were screened by next-generation sequencing. Patients with SLC26A4 mutations underwent a complete audiological evaluation including otoscopic examination, audiometry and morphological evaluation of the inner ear. Results Next generation sequencing analysis of SLC26A4 in 192 CH patients revealed five different heterozygous variations in eight individuals (8/192, 4%). The prevalence of SLC26A4 mutations was 4% among studied Chinese CH. Three of the eight were diagnosed as enlargement of the vestibular aqueduct (EVA), no PS were found in our 192 CH patients. The mutations included one novel missense variant p.P469S, as well as four known missense variants, namely p.V233L, p.M147I, p.V609G and p.D661E. Of the eight patients identified with SLC26A4 variations in our study, seven patients showed normal size/location of thyroid gland, and one patients showed a decreased size one. Conclusions The prevalence of SLC26A4 pathogenic variants was 4% among studied Chinese patients with CH. Our study expanded the SLC26A4 mutation spectrum, provided the best estimation of SLC26A4 mutation rate for Chinese CH patients and indicated the rarity of PS as a cause of CH.

In this article, the hydroxyapatite and carbonate(HAC) nanoparticles were obtained by calcining the original pig bones, and the influence of different calcining temperature on morphology and size was investigated. Then, the polycaprolactone(PCL)/HAC composite materials were synthesized through in-situ polymerization with caprolactone(CL) and HAC. The effects of different weight ratios of HAC to CL on the performance of composites was discussed, and the morphology and microstructure of obtained composite materials were characterized by transmission electron microscopy(TEM), Fourier transform infrared(FT-IR) and (X-ray diffraction)XRD, etc. The results showed that HAC was uniformly dispersed in PCL matrix, and the composite material with HAC of 6 wt% was chosen for further application. This study provided a new way for synthesizing PCL/HAC materials that could be used for repairing and substituting for human damaged bone, which is significant in the theory and practice of bio-medicine.